Neoadjuvant Chemotherapy for Resectable Cancer of the Pancreatic Head
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00490360|
Recruitment Status : Completed
First Posted : June 22, 2007
Last Update Posted : June 22, 2007
|Condition or disease||Intervention/treatment||Phase|
|Cancer of the Pancreatic Head||Drug: Gemcitabine / Cisplatin||Phase 2|
Neodajuvant chemotherapy with gemcitabine / cisplatin is applied to patients with resectable cancer of pancreatic head. Two cycles of chemotherapy are given on day 1 and 15 each. After restaging excludes disease progression, a standard Whipple procedure is performed.
Staging and restaging procedures include abdominal CT, diagnostic laparoscopy, PET/CT, tumor markers (CEA, CA 19-9) and assessment of the quality of life by the QLQ-30.
- Trial with medicinal product
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||2007 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Neoadjuvant Chemotherapy for Resectable Cancer of the Pancreatic Head|
|Study Start Date :||October 2001|
|Actual Study Completion Date :||May 2007|
- Resectability rate > 70% after restaging [ Time Frame: 2007 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00490360
|University Hospital of Zurich, Department of Surgery|
|Study Director:||01 Studienregister MasterAdmins||UniversitaetsSpital Zuerich|